Zacks Investment Research cut shares of BeyondSpring Inc. (NASDAQ:BYSI) from a hold rating to a sell rating in a research note published on Monday morning.
According to Zacks, “BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company’s lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring Inc. is based in New York, United States. “
Several other analysts also recently commented on BYSI. HC Wainwright reaffirmed a buy rating and set a $50.00 price objective on shares of BeyondSpring in a research report on Monday, August 21st. Maxim Group initiated coverage on shares of BeyondSpring in a research report on Tuesday, August 22nd. They set a buy rating and a $52.00 price objective for the company.
Shares of BeyondSpring (NASDAQ:BYSI) opened at $34.37 on Monday. BeyondSpring has a 52-week low of $16.55 and a 52-week high of $48.49.
BeyondSpring (NASDAQ:BYSI) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.01. research analysts predict that BeyondSpring will post -4.41 earnings per share for the current year.
A hedge fund recently bought a new stake in BeyondSpring stock. Tanaka Capital Management Inc. purchased a new stake in BeyondSpring Inc. (NASDAQ:BYSI) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 21,322 shares of the company’s stock, valued at approximately $914,000. BeyondSpring accounts for about 2.1% of Tanaka Capital Management Inc.’s investment portfolio, making the stock its 16th biggest holding. Tanaka Capital Management Inc. owned about 0.10% of BeyondSpring at the end of the most recent quarter. 1.23% of the stock is owned by hedge funds and other institutional investors.
BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related companies with our FREE daily email newsletter.